iGlarLixi vs. premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: SoliComplex real-world study.

In this observational study in people with suboptimally controlled T2D with basal insulin, once daily iGlarLixi was an effective treatment alternative to premixed insulin with significantly higher treatment persistence, similar adherence and HbA1c reduction, and numerically lower hypoglycaemia events, HRU, and costs, regardless of age or baseline HbA1c. This article is protected by copyright. All rights reserved.